# Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

> **NCT01359618** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 16 (actual)

## Conditions studied

- Healthy Male

## Interventions

- **DRUG:** TC-5214
- **OTHER:** Placebo comparator
- **DRUG:** Moxifloxacin
- **OTHER:** Moxifloxacin placebo comparator

## Key facts

- **NCT ID:** NCT01359618
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate
- **Last updated:** 2012-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359618, "Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01359618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*